After entering menopause, I often hear in the consultation room the question "I eat exactly as before, so why does only my belly stick out?" As GLP-1 injections such as Wegovy have become known, people troubled by menopausal obesity and abdominal obesity wonder whether this drug could help them too. Rather than explaining the general principle of Wegovy from the start, this article focuses on what should be weighed together when considering this drug in the special period of menopause. I hope it is read not as an article trying to conclude its effect but as educational material organizing indications and considerations with evidence.
Why is menopausal weight gain different?
The core of menopausal weight change lies in "distribution" rather than "amount." When estrogen decreases around menopause, energy metabolism changes and fat is reported to tend to concentrate in the abdomen and viscera. Even at the same weight, when visceral fat increases more than subcutaneous fat, the risk of insulin resistance and metabolic disease rises together. Materials from various bodies including the North American Menopause Society also explain that a considerable proportion of women in the menopausal transition experience weight gain, and that this is the result of aging and reduced activity overlapping.
In the consultation room, many people blame themselves for this change as "a lack of willpower." But when the hormonal environment changes, the basal metabolic rate and fat distribution themselves change, so the result can appear differently even with the same effort. How menopausal weight gain is intertwined with hormones is addressed in more detail in an article unpacking from a hormonal perspective why you gain weight more easily in menopause. Understanding this background makes clear "for whom, and why" Wegovy becomes a candidate.
Which part of menopausal change does Wegovy touch?
The active ingredient of Wegovy is a GLP-1 (Glucagon-Like Peptide-1) analogue, a prescription injectable that strengthens the action of a hormone secreted from the L cells of our small intestine. GLP-1 works through several pathways after a meal.
- In the hypothalamus of the brain, it suppresses appetite and increases satiety
- It slows the rate of gastric emptying, helping satiety last longer
- In the pancreas, it helps insulin secretion and makes the post-meal blood-sugar rise gentle
Recalling that the very points that become problematic in menopause are appetite regulation, insulin resistance, and visceral fat, you can see that the target Wegovy aims at overlaps considerably with the metabolic changes of menopause. That is, Wegovy is reported as a drug that can simultaneously aim at weight loss and improvement of metabolic indicators, and for this reason it is mentioned as an option that "can be considered" for those who have menopausal obesity, abdominal obesity, and metabolic syndrome together. However, it does not guarantee the same result for everyone, and effect and suitability can have individual differences.
Is an effect actually reported in menopausal women?
Studies targeting menopausal and postmenopausal women are also accumulating. In several clinical materials including overweight and obese women in the perimenopausal age range, a meaningful weight loss was reported after treatment with semaglutide (the ingredient of Wegovy), and this is organized as being at a level similar to premenopausal women despite higher initial weight and body fat (Metabolic Syndrome and Related Disorders, 2024).
An interesting point is the relationship with hormone therapy. In a study published in the journal Menopause in 2024, among postmenopausal women using semaglutide, the group that combined hormone therapy was reported to show a better weight-loss response than the group that did not. The hypothesis is presented that replenishing the decreased estrogen may partly restore a metabolic environment in which the drug works better, but the exact mechanism is still being clarified. This part is information meaningful only in the context of menopause, so if you are receiving or considering hormone therapy, we recommend discussing together whether to combine the two treatments at menopausal hormone therapy care.
Even the same drug can respond differently according to the temporal characteristics of menopause, the hormone state, and accompanying conditions. So rather than the generalization that "Wegovy is good for menopausal women," an individual evaluation weighing benefit and harm in your body state comes first.
Considerations to be especially careful about in menopause
When considering Wegovy for menopausal women, there is a point to attend to differently from general adults. That is muscle and bone. It is pointed out in various materials that, when weight comes off with GLP-1-class drugs, part of the weight lost is not fat but lean mass (muscle, etc.). Yet menopausal women, by estrogen decrease alone, are in a period when muscle mass naturally decreases each year and bone density is also prone to dropping.
| Consideration area | Existing vulnerability of menopausal women | Management recommended together |
|---|---|---|
| Muscle mass | Muscle loss progresses after menopause | Sufficient protein intake, regular strength training |
| Bone health | Increased bone-loss risk due to estrogen decrease | Bone density assessment, calcium and vitamin D check |
| Nutrition | Intake itself can decrease due to reduced appetite | Balanced diet, regular monitoring |
The U.S. Endocrine Society advises that increasing protein intake during GLP-1 treatment can help reduce muscle loss (2025). Likewise, in menopause it is safe to approach not by looking at the drug alone but on the premise of combining it with lifestyle habits. If you are worried about bone health, we recommend also reading an article addressing bone health for women over 50.
Side effects and cases where prescription is difficult
No matter how helpful a drug can be, side effects and contraindications must be confirmed. The reactions relatively commonly reported with Wegovy are gastrointestinal symptoms such as nausea, vomiting, diarrhea, constipation, and temporary loss of appetite. Most tend to decrease in the process of adapting while slowly raising the dose, but there are individual differences. Rarely, pancreatitis, gallstones, and so on are reported, so if newly arising abdominal pain persists, immediate care is needed.
In the following cases, prescription is restricted or careful judgment is needed.
- During pregnancy, while planning pregnancy, or while breastfeeding
- When there is a past history of pancreatic disease
- When gastrointestinal disease is severe
- When there is a history related to certain medullary thyroid cancer or endocrine tumors
Since menopausal women are in a period when they are already taking other drugs or have many items to check in screening, it is good to check the overall health state before starting. If you want to quickly confirm whether you are a suitable candidate and which side effects to watch for, please inquire comfortably through the consult about menopausal weight concerns channel.
It is not a problem that ends with Wegovy alone
I want to emphasize that menopausal weight management is not a problem completed with a single drug. In clinical experience, those who show the best results are those who, rather than relying on the drug alone, organize their eating habits, strength training, sleep, and even hormone state together. Wegovy can help with one axis, appetite and metabolism, but reduced muscle, bone health, and hormonal change need separate management.
There are also many realistic questions, such as whether weight can rise again after stopping, and until when it must be maintained. Such parts can be checked in the guidance on the possibility of rebound weight gain after stopping a GLP-1 diet injection and the summary of side effects of diet injections. In the end, rather than approaching Wegovy with the short answer of "should I use it or not," it is right to position it within the whole picture fitted to your menopausal body state.
In closing: consultation comes first
Wegovy can be a meaningful option when considering improvement of menopausal obesity, abdominal obesity, and metabolic syndrome, but effect and suitability have individual differences, and the variables unique to menopause—muscle, bone, and hormones—must be viewed together. Rather than concluding the effect, it is safe to decide whether to start after sufficiently confirming the indications and considerations.
If you are troubled by abdominal obesity or menopausal weight change, we recommend setting a direction that fits you based on menopause screening, which looks at the hormone state and screening results together. If you need a more detailed consultation, you can inquire through the menopausal weight and metabolism consultation channel.
Written by: Lee Dong-hee Director · OB-GYN specialist · View medical staff profile
First published August 14, 2025 · Last reviewed May 30, 2026
References: North American Menopause Society materials (2024), Menopause (2024), Metabolic Syndrome and Related Disorders (2024), U.S. Endocrine Society (2025)
This article is intended to provide general health information and does not replace individual diagnosis or treatment. If you have symptoms, please consult through an examination.